ADMA Q3 2020 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+42.3% YoY

Gross Profit

-$2M-15.4% margin

Operating Income

-$14M-134.3% margin

Net Income

-$17M-164.6% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+32.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$27M

Stock-Based Comp.

$774,784

Balance Sheet

Total Assets

$190M

Total Liabilities

$119M

Stockholders' Equity

$71M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$7M	+42.3%
Gross Profit	-$2M	-$693,717	-127.6%
Operating Income	-$14M	-$9M	-52.5%
Net Income	-$17M	-$11M	-47.9%